vs
QuidelOrtho Corp（QDEL）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
RANGE RESOURCES CORP的季度营收约是QuidelOrtho Corp的1.1倍（$786.9M vs $699.9M），RANGE RESOURCES CORP净利率更高（22.8% vs -104.7%，领先127.5%），RANGE RESOURCES CORP同比增速更快（18.0% vs -3.7%），过去两年RANGE RESOURCES CORP的营收复合增速更高（14.6% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
QDEL vs RRC — 直观对比
营收规模更大
RRC
是对方的1.1倍
$699.9M
营收增速更快
RRC
高出21.7%
-3.7%
净利率更高
RRC
高出127.5%
-104.7%
两年增速更快
RRC
近两年复合增速
-2.9%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $786.9M |
| 净利润 | $-733.0M | $179.1M |
| 毛利率 | — | 94.5% |
| 营业利润率 | -100.7% | — |
| 净利率 | -104.7% | 22.8% |
| 营收同比 | -3.7% | 18.0% |
| 净利润同比 | -3583.4% | 88.8% |
| 每股收益（稀释后） | $-10.78 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELRRC
| Q4 25 | — | $786.9M | ||
| Q3 25 | $699.9M | $655.3M | ||
| Q2 25 | $613.9M | $699.6M | ||
| Q1 25 | $692.8M | $846.3M | ||
| Q4 24 | $707.8M | $667.0M | ||
| Q3 24 | $727.1M | $567.9M | ||
| Q2 24 | $637.0M | $513.2M | ||
| Q1 24 | $711.0M | $598.8M |
净利润QDELRRC
| Q4 25 | — | $179.1M | ||
| Q3 25 | $-733.0M | $144.3M | ||
| Q2 25 | $-255.4M | $237.6M | ||
| Q1 25 | $-12.7M | $97.1M | ||
| Q4 24 | $-178.4M | $94.8M | ||
| Q3 24 | $-19.9M | $50.7M | ||
| Q2 24 | $-147.7M | $28.7M | ||
| Q1 24 | $-1.7B | $92.1M |
毛利率QDELRRC
| Q4 25 | — | 94.5% | ||
| Q3 25 | — | 92.5% | ||
| Q2 25 | — | 95.0% | ||
| Q1 25 | — | 93.1% | ||
| Q4 24 | — | 93.7% | ||
| Q3 24 | — | 94.3% | ||
| Q2 24 | — | 93.4% | ||
| Q1 24 | — | 94.7% |
营业利润率QDELRRC
| Q4 25 | — | — | ||
| Q3 25 | -100.7% | — | ||
| Q2 25 | -29.4% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | -14.2% | — | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | -18.4% | — | ||
| Q1 24 | -247.3% | — |
净利率QDELRRC
| Q4 25 | — | 22.8% | ||
| Q3 25 | -104.7% | 22.0% | ||
| Q2 25 | -41.6% | 34.0% | ||
| Q1 25 | -1.8% | 11.5% | ||
| Q4 24 | -25.2% | 14.2% | ||
| Q3 24 | -2.7% | 8.9% | ||
| Q2 24 | -23.2% | 5.6% | ||
| Q1 24 | -239.9% | 15.4% |
每股收益（稀释后）QDELRRC
| Q4 25 | — | $0.75 | ||
| Q3 25 | $-10.78 | $0.60 | ||
| Q2 25 | $-3.77 | $0.99 | ||
| Q1 25 | $-0.19 | $0.40 | ||
| Q4 24 | $-2.54 | $0.38 | ||
| Q3 24 | $-0.30 | $0.21 | ||
| Q2 24 | $-2.20 | $0.12 | ||
| Q1 24 | $-25.50 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $204.0K |
| 总债务越低越好 | $2.5B | $1.2B |
| 股东权益账面价值 | $2.0B | $4.3B |
| 总资产 | $5.7B | $7.4B |
| 负债/权益比越低杠杆越低 | 1.23× | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资QDELRRC
| Q4 25 | — | $204.0K | ||
| Q3 25 | $98.1M | $175.0K | ||
| Q2 25 | $151.7M | $134.0K | ||
| Q1 25 | $127.1M | $344.6M | ||
| Q4 24 | $98.3M | $304.5M | ||
| Q3 24 | $143.7M | $277.4M | ||
| Q2 24 | $107.0M | $251.1M | ||
| Q1 24 | $78.5M | $343.1M |
总债务QDELRRC
| Q4 25 | — | $1.2B | ||
| Q3 25 | $2.5B | $1.2B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $2.1B | $1.7B | ||
| Q4 24 | $2.1B | $1.7B | ||
| Q3 24 | $2.2B | $1.7B | ||
| Q2 24 | $2.2B | $1.7B | ||
| Q1 24 | $2.2B | $1.8B |
股东权益QDELRRC
| Q4 25 | — | $4.3B | ||
| Q3 25 | $2.0B | $4.2B | ||
| Q2 25 | $2.8B | $4.1B | ||
| Q1 25 | $3.0B | $3.9B | ||
| Q4 24 | $3.0B | $3.9B | ||
| Q3 24 | $3.2B | $3.9B | ||
| Q2 24 | $3.2B | $3.9B | ||
| Q1 24 | $3.3B | $3.8B |
总资产QDELRRC
| Q4 25 | — | $7.4B | ||
| Q3 25 | $5.7B | $7.2B | ||
| Q2 25 | $6.4B | $7.1B | ||
| Q1 25 | $6.5B | $7.4B | ||
| Q4 24 | $6.4B | $7.3B | ||
| Q3 24 | $6.8B | $7.2B | ||
| Q2 24 | $6.7B | $7.3B | ||
| Q1 24 | $6.7B | $7.4B |
负债/权益比QDELRRC
| Q4 25 | — | 0.28× | ||
| Q3 25 | 1.23× | 0.29× | ||
| Q2 25 | 0.74× | 0.29× | ||
| Q1 25 | 0.70× | 0.43× | ||
| Q4 24 | 0.72× | 0.43× | ||
| Q3 24 | 0.68× | 0.44× | ||
| Q2 24 | 0.70× | 0.44× | ||
| Q1 24 | 0.68× | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $257.5M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | — |
| 自由现金流率自由现金流/营收 | -13.5% | — |
| 资本支出强度资本支出/营收 | 7.0% | — |
| 现金转化率经营现金流/净利润 | — | 1.44× |
| 过去12个月自由现金流最近4个季度 | $-153.1M | — |
8季度趋势，按日历期对齐
经营现金流QDELRRC
| Q4 25 | — | $257.5M | ||
| Q3 25 | $-45.5M | $247.5M | ||
| Q2 25 | $-46.8M | $336.2M | ||
| Q1 25 | $65.6M | $330.1M | ||
| Q4 24 | $63.7M | $217.9M | ||
| Q3 24 | $117.9M | $245.9M | ||
| Q2 24 | $-97.9M | $148.8M | ||
| Q1 24 | $-700.0K | $331.9M |
自由现金流QDELRRC
| Q4 25 | — | — | ||
| Q3 25 | $-94.7M | — | ||
| Q2 25 | $-84.3M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $71.4M | — | ||
| Q2 24 | $-133.2M | — | ||
| Q1 24 | $-66.8M | — |
自由现金流率QDELRRC
| Q4 25 | — | — | ||
| Q3 25 | -13.5% | — | ||
| Q2 25 | -13.7% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | -20.9% | — | ||
| Q1 24 | -9.4% | — |
资本支出强度QDELRRC
| Q4 25 | — | — | ||
| Q3 25 | 7.0% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 8.1% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 6.4% | — | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 9.3% | — |
现金转化率QDELRRC
| Q4 25 | — | 1.44× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 3.40× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 4.85× | ||
| Q2 24 | — | 5.18× | ||
| Q1 24 | — | 3.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
